List of Excipients in Branded Drug INSULIN ASPART

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	INSULIN ASPART	insulin aspart	50090-4955	GLYCERIN
A-S Medication Solutions	INSULIN ASPART	insulin aspart	50090-4955	HYDROCHLORIC ACID
A-S Medication Solutions	INSULIN ASPART	insulin aspart	50090-4955	METACRESOL
A-S Medication Solutions	INSULIN ASPART	insulin aspart	50090-4955	PHENOL
A-S Medication Solutions	INSULIN ASPART	insulin aspart	50090-4955	SODIUM CHLORIDE

Last updated: September 24, 2026

Insulin aspart has two distinct excipient strategies: the conventional NovoLog/NovoRapid formulation, which prioritizes long-term stability and established manufacturing, and Fiasp, which adds niacinamide and arginine to accelerate subcutaneous absorption. The strongest commercial opportunities are in rapid-acting insulin delivery, pump-compatible presentations, lower-cost biosimilar or follow-on products, preservative and container-closure systems, and excipient platforms that improve absorption without changing the insulin molecule.

Insulin Aspart Excipient Strategy and Commercial Opportunities

What excipients are used in insulin aspart products?

Insulin aspart products use excipients to control pH, preserve sterility, stabilize the insulin hexamer, limit aggregation, and maintain delivery performance during storage and administration.

Product	Active ingredient	Key excipients	Commercial purpose
NovoLog/NovoRapid	Insulin aspart	Glycerol, phenol, metacresol, zinc, disodium phosphate, sodium chloride, hydrochloric acid, sodium hydroxide, water	Conventional rapid-acting insulin stability and preservation
Fiasp	Insulin aspart	Niacinamide, arginine, glycerol, phenol, metacresol, zinc, disodium phosphate, sodium chloride, hydrochloric acid, sodium hydroxide, water	Faster initial absorption and preserved formulation stability
Insulin aspart in pumps	Insulin aspart	Generally the approved multidose-vial formulation	Compatibility with continuous subcutaneous insulin infusion
Pen and cartridge presentations	Insulin aspart	Same formulation as the corresponding vial, with container-closure and device materials added to the product system	Convenience, dose accuracy, and adherence

The exact quantitative composition is product-specific and should be taken from the approved label rather than inferred from general insulin formulation practice. FDA labeling identifies the excipients and concentration for U.S. products [1, 2].

What does each excipient do?

Glycerol helps maintain tonicity and contributes to formulation stability. Phenol and metacresol act as antimicrobial preservatives and influence the conformation of insulin in the formulation. Zinc supports insulin association and structural stability. Phosphate provides buffering capacity. Sodium chloride adjusts ionic strength and tonicity. Hydrochloric acid and sodium hydroxide adjust pH.

Fiasp adds niacinamide, also known as nicotinamide or vitamin B3, and arginine. Niacinamide increases the early availability of insulin aspart after subcutaneous injection. Arginine supports formulation stability and helps manage the physical behavior of the insulin preparation. Novo Nordisk’s clinical and regulatory materials associate the Fiasp excipient system with faster early absorption than conventional insulin aspart [2, 3].

How does Fiasp’s excipient strategy differ from NovoLog and NovoRapid?

Fiasp is not a new insulin molecule. It is an insulin aspart formulation with an absorption-enhancing excipient system.

The commercial distinction is therefore based on pharmacokinetics, administration timing, device presentation, and clinical positioning rather than molecular differentiation.

Attribute	NovoLog/NovoRapid	Fiasp
Insulin molecule	Insulin aspart	Insulin aspart
Absorption strategy	Conventional rapid-acting formulation	Niacinamide-enabled faster initial absorption
Additional functional excipients	None specifically marketed as an absorption enhancer	Niacinamide and arginine
Meal-time positioning	Commonly administered before meals	Can be administered at the start of a meal and, in certain labeling, shortly after meal start
Primary differentiation	Established product, broad use, pump availability	Faster onset and flexible meal timing
Main commercial risk	Price erosion and biosimilar or follow-on competition	Reimbursement pressure and possible substitution by ultra-rapid insulin lispro or other analogues

The Fiasp approach demonstrates a commercially important pathway: an established biologic can be differentiated through excipient engineering without changing its amino-acid sequence. That strategy can support new regulatory filings, new branding, and premium pricing, although the sponsor must establish formulation quality, pharmacokinetics, clinical performance, device compatibility, and stability.

What commercial opportunities exist for insulin aspart excipients?

The opportunity set is concentrated in five areas.

Absorption-enhancing excipient systems

Niacinamide is the clearest validated example. Other candidates may seek to improve monomer availability, capillary transport, or local dispersion after injection. Potential platforms include permeation modifiers, vasodilatory excipients, surfactants, and engineered depot-disrupting systems.

The commercial hurdle is that faster absorption must translate into a clinically useful dosing profile without increasing hypoglycemia, injection-site reactions, immunogenicity, or manufacturing variability.

Preservative and stability systems

Phenol and metacresol are established preservatives, but they can create formulation and tolerability constraints. Opportunities include:

• Lower-preservative multidose systems.
• Alternative antimicrobial preservation.
• Improved resistance to agitation and temperature excursions.
• Reduced fibrillation and aggregation during pump use.
• Longer in-use stability after opening.
• Formulations optimized for concentrated insulin aspart.

A replacement preservative must preserve sterility without destabilizing insulin or altering its pharmacodynamic profile. A change to a preserved multidose insulin is a high-risk development program because the excipient performs both microbiological and structural functions.

Pump-compatible formulations

Insulin aspart is used in continuous subcutaneous insulin infusion. Pump use creates stress conditions that are less important for occasional injection, including prolonged exposure to tubing, reservoirs, heat, mechanical movement, air-liquid interfaces, and contact with device materials.

Excipient suppliers can compete by offering stabilizer systems that reduce:

• Fibril formation.
• Adsorption to reservoir and tubing surfaces.
• Occlusion risk.
• Potency loss during extended in-use periods.
• Interaction with silicone oil, elastomers, adhesives, and plastics.

A formulation that performs well in vials may not perform identically in a pump reservoir. Pump compatibility therefore creates a separate technical and regulatory value proposition.

Pen, cartridge, and connected-device formulations

For insulin aspart, the formulation cannot be separated from the delivery system. Pen and cartridge products require compatibility with glass, elastomeric closures, lubricants, dose mechanisms, and, increasingly, connected-device components.

Commercial opportunities include:

• Prefilled pen systems.
• Cartridges for reusable pens.
• Lower-waste delivery systems.
• High-concentration products that reduce injection volume.
• Formulations designed for automated insulin delivery.
• Packaging with improved temperature protection.
• Device-compatible products for emerging markets.

The excipient package may be unchanged, but container-closure interactions, extractables and leachables, adsorption, and device performance can create patentable and regulatory differentiation.

Lower-cost follow-on products

The largest volume opportunity is likely to come from products that reproduce conventional insulin aspart performance at lower cost. Potential business models include:

• Biosimilar or follow-on insulin aspart.
• Regional manufacturing and licensing.
• Authorized-generic supply.
• Contract manufacturing of vials, cartridges, and pens.
• Local fill-finish and device assembly.
• Institutional products for hospitals and public tenders.

The product must match the reference formulation closely enough to support a manageable comparability package while preserving manufacturing flexibility. Excipients are central to that balance.

What is the FDA regulatory status of insulin aspart and its excipients?

NovoLog was approved by FDA in 2000 as a rapid-acting insulin aspart product. Fiasp was approved in 2017 as an insulin aspart formulation with faster absorption [1, 2].

Insulin products are regulated as biologics under the Public Health Service Act. FDA’s biosimilar framework allows developers to pursue insulin products through the 351(k) pathway. The regulatory package can include analytical similarity, pharmacokinetic and pharmacodynamic studies, immunogenicity, manufacturing comparability, and product-specific clinical evidence [4].

An excipient change can have different regulatory consequences depending on the product and the claimed differentiation:

Change	Likely regulatory significance
Substitution of buffer or tonicity agent	May require extensive comparability and stability data
Change in preservative	High significance because of sterility, tolerability, and multidose use
Addition of absorption enhancer	May create a new formulation or new product claim
Change in concentration	May affect safety, dosing, device performance, and labeling
Change in container-closure system	Requires compatibility, extractables, leachables, and stability assessment
Excipient change in a biosimilar	Must not undermine analytical or clinical similarity to the reference product

FDA’s inactive-ingredient database can support preliminary excipient selection, but prior use in another product does not establish suitability for insulin aspart. The excipient must be appropriate for route, dose, concentration, exposure, and formulation function [5].

What patents protect insulin aspart formulations?

The original insulin aspart composition and conventional formulation patents are mature. Insulin aspart itself was disclosed in early insulin analogue patent families, including Novo Nordisk-related filings such as U.S. Patent No. 5,474,978. Core composition protection has expired in the United States.

Current patent value is more likely to arise from secondary claims covering:

• Niacinamide-containing insulin formulations.
• Arginine and related stabilizer combinations.
• Dosing regimens and meal-time administration.
• Pump use and in-use stability.
• Pen, cartridge, and reservoir systems.
• Concentrated insulin aspart.
• Manufacturing processes and purification.
• Specific excipient ratios or concentration ranges.
• Combination use with automated insulin delivery systems.

Fiasp-type formulation patents are more commercially relevant than the original insulin aspart molecule patents. Patent scope must be assessed claim by claim because a broad composition claim may be weakened by prior art, while narrower claims directed to concentration ranges, excipient combinations, or use conditions may remain enforceable.

What is the Orange Book status of insulin aspart?

FDA’s Orange Book is relevant to approved drug products listed under the applicable regulatory framework, but biologic exclusivity and patent analysis for insulin products also require review of the Purple Book, FDA approval records, patent listings, and jurisdiction-specific registers [6, 7].

A commercial diligence review should separate:

1. The insulin aspart molecule.
2. The conventional formulation.
3. The Fiasp formulation.
4. The pen and cartridge device.
5. The pump presentation.
6. Method-of-use and dosing claims.
7. Manufacturing and process claims.

Patent expiration for the original molecule does not remove risk from later formulation or device patents.

When does insulin aspart lose exclusivity?

The original insulin aspart molecule has already lost basic composition-of-matter exclusivity in the United States. The commercial exclusivity question now concerns product-specific formulation, regulatory, device, and process rights.

Exclusivity layer	Status or commercial implication
Original insulin aspart molecule	Mature and no longer the primary barrier
NovoLog/NovoRapid conventional formulation	Subject to product, formulation, device, and regulatory competition
Fiasp formulation	Potentially protected by later formulation and use patents
FDA reference-product exclusivity	Depends on the applicable biologic pathway and approval history
Pen and cartridge systems	May have separate device and combination-product protection
Pump-use presentation	May involve formulation, device, and method-of-use claims

Exact U.S. entry timing depends on the reference product, the applicant’s pathway, patent certifications, litigation, settlement terms, and any regulatory exclusivity remaining at the time of filing.

Which companies are challenging insulin aspart commercially?

Competition comes from several groups rather than a single direct challenger.

Novo Nordisk remains the originator and markets NovoLog/NovoRapid and Fiasp. Sanofi competes with insulin glulisine through Apidra. Eli Lilly competes with insulin lispro through Humalog and Lyumjev, with Lyumjev using a formulation strategy intended to accelerate absorption. Biocon Biologics, Wockhardt, Julphar, Ypsomed-related partners, and regional insulin manufacturers participate in broader insulin and follow-on markets, although product approvals and availability differ by country.

Walmart’s ReliOn NovoLog has also expanded price competition in the United States through a branded retail channel supplied by Novo Nordisk. It is not equivalent to a fully independent insulin-aspart biosimilar.

How does insulin aspart compare with insulin lispro and insulin glulisine?

Product	Molecule	Excipient differentiation	Primary competitive issue
NovoLog/NovoRapid	Insulin aspart	Conventional stabilizer and preservative system	Price, access, and established pump use
Fiasp	Insulin aspart	Niacinamide and arginine	Faster onset and premium positioning
Humalog	Insulin lispro	Conventional rapid-acting formulation	Broad market presence
Lyumjev	Insulin lispro	Formulation designed for faster absorption	Direct ultra-rapid competition
Apidra	Insulin glulisine	Distinct insulin analogue and formulation	Hospital, retail, and regional access

The primary commercial differentiator is not whether a product contains insulin aspart, lispro, or glulisine. It is the combined effect of absorption profile, price, formulary position, pen availability, pump labeling, supply reliability, and patient switching friction.

What generic entry risks exist for insulin aspart?

Generic entry risk is moderate to high for conventional insulin aspart and more complex for Fiasp-like products.

Conventional insulin aspart

The molecule is mature, and the formulation uses widely known excipients. This supports biosimilar or follow-on development. The main barriers are manufacturing consistency, insulin aggregation control, analytical characterization, device integration, and commercial scale.

Fiasp-type insulin aspart

The addition of niacinamide and arginine creates more differentiation. A competitor may pursue a close follow-on formulation, but it must address:

• Comparative early insulin exposure.
• Postprandial glucose control.
• Excipient-related tolerability.
• Stability during pump use.
• Manufacturing control of excipient concentration.
• Formulation and method-of-use patents.
• Device and presentation rights.

Biosimilar risk

Insulin aspart is more accessible to biosimilar developers than complex monoclonal antibodies because it is a relatively small, well-characterized protein. Its manufacturing process remains difficult. Small changes in folding, deamidation, aggregation, zinc association, or excipient interaction can affect quality and clinical behavior.

The most exposed segment is standard vial and pen insulin aspart. Fiasp, concentrated presentations, and integrated pump products have higher technical and IP barriers.

What licensing and partnership opportunities exist?

The most attractive licensing structures are likely to involve technology rather than the insulin molecule itself.

Potential transactions include:

• Regional licenses for insulin aspart fill-finish.
• Co-development of lower-cost biosimilar insulin aspart.
• Licensing of niacinamide-based absorption platforms.
• Supply agreements for high-purity niacinamide, arginine, zinc, or preservatives.
• Pen and cartridge partnerships.
• Pump-reservoir and automated-delivery collaborations.
• Formulation technology transfers to emerging-market manufacturers.
• Authorized-generic or private-label supply agreements.

A licensor with a differentiated excipient system can seek value through formulation patents, manufacturing know-how, regulatory files, and device compatibility data. A generic manufacturer may prefer a supply or technology-transfer deal because independent development of insulin fermentation, purification, sterile fill-finish, and device assembly is capital-intensive.

How strong is the insulin aspart patent estate?

The estate is strongest around differentiated formulations, devices, and manufacturing know-how. It is weaker around the basic insulin aspart molecule.

Patent category	Relative strength
Original insulin aspart molecule	Low, because core rights are mature
Conventional excipient formulation	Low to moderate, depending on claim scope
Fiasp-like absorption-enhancing system	Moderate to high where valid claims remain
Pump stability and reservoir compatibility	Moderate
Pen and cartridge systems	Moderate, with significant design-around potential
Manufacturing and purification	Moderate to high if process know-how is difficult to replicate
Method-of-use claims	Variable and vulnerable to label-based design-around

Patent strength depends on jurisdiction, prosecution history, written-description support, enablement, prior art, and the practical ability to design around the claimed excipient ranges.

What revenue exposure does insulin aspart create?

Novo Nordisk reports revenue across broader insulin categories and does not consistently disclose standalone global sales for every insulin aspart presentation. Public filings therefore do not support a precise worldwide revenue figure for NovoLog, NovoRapid, and Fiasp as a combined group [8].

Commercial exposure is still material because insulin aspart participates in:

• Retail diabetes treatment.
• Hospital insulin use.
• Continuous insulin infusion.
• Pen and cartridge markets.
• Automated insulin delivery.
• Public reimbursement and tender systems.

Revenue risk is highest where payers can substitute conventional insulin aspart or another rapid-acting analogue with limited clinical disruption. Premium products such as Fiasp are more exposed to formulary restrictions unless faster absorption produces measurable adherence or glycemic benefits.

Key Takeaways

• Conventional insulin aspart relies on a mature excipient system built around glycerol, phenol, metacresol, zinc, phosphate, sodium chloride, and pH control.
• Fiasp adds niacinamide and arginine to accelerate early absorption without changing the insulin molecule.
• The strongest commercial opportunities are absorption enhancement, pump stability, lower-cost follow-on insulin, pen and cartridge systems, and manufacturing partnerships.
• Original insulin aspart molecule protection is mature; remaining value is concentrated in formulation, device, process, and method-of-use claims.
• Conventional insulin aspart faces greater follow-on risk than Fiasp-type products.
• Excipient changes can create meaningful differentiation but require extensive comparability, stability, safety, and device data.
• Public filings do not consistently disclose standalone insulin aspart revenue, so product-specific revenue exposure cannot be reliably quantified from company reports alone.

FAQs About Insulin Aspart Excipient Strategy

Can niacinamide be used to create a faster insulin aspart product?

Yes. Fiasp demonstrates that niacinamide can be used in an insulin aspart formulation to increase early absorption. A new product would still need to establish formulation performance, safety, manufacturing control, and freedom to operate.

Is insulin aspart compatible with insulin pumps?

Approved insulin aspart products are used in continuous subcutaneous insulin infusion, subject to the product label and pump instructions. Pump compatibility depends on both insulin formulation and the specific pump, reservoir, tubing, and wear period.

Can a biosimilar insulin aspart use different excipients?

Potentially, but different excipients can complicate the similarity assessment. A developer must show that the change does not alter pharmacokinetics, pharmacodynamics, immunogenicity, stability, delivery, or clinical performance.

What is the highest-value excipient opportunity in rapid-acting insulin?

Absorption-enhancing systems have the highest differentiation potential because they can support faster onset claims. Pump-stability systems may have equal or greater value in automated insulin delivery, where formulation performance directly affects device reliability.

Does a new insulin aspart excipient combination receive new patent protection?

It can, if the combination is novel, non-obvious, adequately described, enabled, and commercially useful. Patentability is stronger when the excipient combination produces an unexpected absorption, stability, or device-compatibility result.

References

1. U.S. Food and Drug Administration. (2000). NovoLog insulin aspart injection, prescribing information. FDA.

2. U.S. Food and Drug Administration. (2017). Fiasp insulin aspart injection, prescribing information. FDA.

3. Heise, T., Pieber, T. R., Danne, T., Erichsen, L., & Haahr, H. (2017). A pooled analysis of the pharmacological and clinical profile of faster-acting insulin aspart. Clinical Pharmacokinetics, 56(5), 551-559.

4. U.S. Food and Drug Administration. (2015). Biosimilars: Questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. FDA.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

7. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

8. Novo Nordisk A/S. (2024). Annual report 2023. Novo Nordisk.